GA
UTHR icon

Geneva Advisors’s United Therapeutics UTHR Stock Holding History

Geneva Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,920
Closed -$848K – 713
2015
Q1 		$848K Buy
+4,920
New +$750K 0.02% 332

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Geneva Advisors's UTHR Position: Q2 2015 in Review

Geneva Advisors sold out of United Therapeutics (UTHR) in Q2 2015, closing a stake of 4,920 shares — an estimated $848K sold.

Geneva Advisors first reported a position in UTHR in Q1 2015 and held it in 1 quarter. The position peaked at $848K in Q1 2015. 383 funds tracked by Wall St. Rank hold UTHR as of Q2 2015.

  • Geneva Advisors reported no remaining United Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Geneva Advisors sold 4,920 United Therapeutics shares in Q2 2015, an estimated $848K.
  • Geneva Advisors first reported a position in United Therapeutics in Q1 2015 and held it in 1 quarter.
  • Geneva Advisors's United Therapeutics position peaked at $848K in Q1 2015.
  • 383 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2015.

Based on Geneva Advisors's 13F filing for Q2 2015, filed 3 Aug 2015.